Cadrenal Therapeutics, Inc. CMO Resignation; Separation Agreement Filed

What Happened
Cadrenal Therapeutics, Inc. announced that Chief Medical Officer James J. Ferguson III notified the Board on July 7, 2026 of his decision to resign, with a Separation Date of July 31, 2026. The company and Dr. Ferguson entered into a confidential Separation Agreement and General Release dated July 9, 2026 (executed July 14, 2026). The company is actively searching for a replacement.

Key Details

• Separation Agreement dated July 9, 2026 and entered into July 14, 2026 with a seven-day revocation period following execution. A second release executed on the Separation Date is also subject to a seven-day revocation period before certain benefits commence.
• Dr. Ferguson will receive: (1) payment of his salary through July 31, 2026; (2) company-paid COBRA premiums at 100% for up to six months after the Separation Date, unless he becomes eligible for new employer coverage or loses COBRA eligibility; and (3) approved, unreimbursed business expenses.
• The agreement includes a general release of claims and a non-disparagement clause. A copy of the Separation Agreement is filed as Exhibit 10.1.

Why It Matters
This is an executive leadership change for Cadrenal’s clinical/medical function, which investors may view as relevant to ongoing clinical programs and management continuity. Financially, the filing discloses limited, defined obligations (salary through July 31, COBRA premiums for up to six months, and expense reimbursement) rather than a large lump-sum severance; certain payments are contingent on execution and non-revocation of releases. The company’s continued search for a CMO replacement is underway.